Patient-reported Outcomes (PRO) and Treatment Outcomes of Chinese Patients With MSS-type Advanced Colorectal Cancer Who Received the Zidovudine Combination Regimen in the Real World
The Chidamide + sintilimab ± bevacizumab regimen has become a post-treatment option for clinicians and patients after being included in the guidelines. The CAPability-01 study is a phase II RCT, with a limited number of enrolled subjects. Further observation of the safety and clinical real-world application status of the sidibemab combination regimen is needed in a larger sample size prospective observational cohort study. The primary endpoint of this study is the safety events of the sidibemab combination regimen.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Age ≥ 18 years old, gender not restricted;
2. Advanced colorectal cancer confirmed by histopathology; and confirmed as MSS/pMMR type by immunohistochemistry or genetic testing;
3. The investigators evaluate that the treatment regimen of cediranib combined with immune checkpoint inhibitors is applicable;
4. Clear consciousness, able to answer questions correctly;
5. Capable of using mobile phones and accessing the internet, with 3G/4G/5G function of smart mobile devices.
Exclusion Criteria:
1. There are serious complications that interfere with the efficacy and safety analysis;
2. The investigators determined that the subjects were not suitable for inclusion in this study.
Primary outcome measure(s)
Grade 3-4 adverse effects rate — From date of randomization until the date of death from any cause, assessed up to 2 years] Rate of HDACi and immunotherapy and others treatments related severe adverse events
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.